Frontier Medicines hands LG Chem license to first-in-class p53 Y220C activator

FMC-220, a covalent small molecule described by Frontier Medicines as a first-in-class activator of the p53 Y220C mutant protein, is the subject of an exclusive licensing agreement granting LG Chem, Ltd (KRX: 051910) worldwide development and commercialization rights outside of Greater China. Frontier Medicines, a private clinical-stage company based in Boston and South San Francisco, retains full ownership of the asset within Greater China.

Under the terms of the agreement, Frontier will receive an undisclosed upfront payment and is eligible for clinical, regulatory, and commercial milestone payments, plus royalties on net sales ranging from mid-single-digit to double-digit percentages. LG Chem will assume responsibility for global clinical development, regulatory filings, manufacturing, and commercialization within its licensed territory. Frontier retains an option to partially fund the confirmatory clinical trial, which would entitle it to enhanced milestone and royalty payments.

Deal context

FMC-220 targets the Y220C point mutation in TP53, a substitution that introduces a neomorphic cysteine residue into the p53 protein and destabilizes its folded structure. Frontier describes FMC-220 as covalently engaging this mutant cysteine — a site absent in wild-type p53 — to reactivate the protein's tumor suppressor function. The TP53 Y220C mutation occurs in approximately 1%–3% of cancers, with prevalence in lung, breast, ovarian, and colorectal tumors. Because p53 lacks a classical enzymatic active site, it has historically resisted small molecule drug discovery; covalent targeting of the mutation-specific cysteine represents a mechanistic approach to circumventing that barrier.

Preclinical data presented at the American Association for Cancer Research Annual Meeting in 2025 showed potency, selective target engagement, and durable anti-tumor activity at low doses across multiple tumor models, including those carrying co-mutations in KRAS. Financial terms beyond the royalty range were not disclosed.

FMC-220 was discovered using Frontier's proprietary Frontier Platform, which integrates chemoproteomics and AI to identify covalent binding sites across the proteome. The platform maps reactive cysteines on proteins that lack conventional druggable pockets, then uses machine learning to prioritize and optimize covalent fragment hits. FMC-220 is the second program to advance from the platform; the first, FMC-376, is a dual ON/OFF KRAS G12C inhibitor currently in clinical development.

Frontier's pipeline context includes its ongoing collaboration with AbbVie, announced in December 2020, under which AbbVie received rights to programs emerging from the Frontier Platform across oncology, immunology, and E3 ligase biology in exchange for a USD 55 million upfront payment, up to USD 45 million in near-term milestones, R&D cost reimbursement, and more than USD 1 billion in potential development and commercial milestones. A milestone payment under that collaboration was disclosed in July 2024, tied to advancement of a lead candidate targeting a transcription factor.

The TP53 mutation space has attracted sustained industry attention given the frequency of p53 alterations across tumor types, but approved therapies directly targeting mutant p53 remain absent. APR-246 (eprenetapopt), which reactivates multiple p53 mutants through a covalent mechanism involving the PRIMA-1 scaffold, reached Phase III in myeloid malignancies but has not achieved regulatory approval in solid tumors. FMC-220's selectivity for the Y220C variant, as described by Frontier, distinguishes it mechanistically from pan-mutant reactivators, though clinical validation of that selectivity profile remains pending.

---

Spot something wrong? Report an issue with this article